One potential candidate IC for cancer patients is IL-2-anti-IL-2 complex (IL-2 IC), which could extend IL-2 bioactivity from hours to days.92 Furthermore, the antibody component in the IC can be manipulated to interact with specific cellular receptors, focusing IL-2 towards specific cells such as CD8+ T cells, NK cells, and Treg cells. This evidence concerns the gene CD8A and cancer.